ACET Adicet Bio, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ACET matters now
Adicet Bio, Inc. (ACET) is a US stock in Healthcare. The latest InvestLog snapshot shows $8.83 with -1.23% on the session and $82.5M in market capitalization; recent performance reads 1-month +11.72% and YTD -3.80%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-20.2M, and EPS of $-1.88. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -121.0%.
The latest indexable market news headline is "Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $18.00; recent insider activity includes RA CAPITAL MANAGEMENT, L.P. filing J-Other. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.62
P/S
0.00
EV/EBITDA
-0.52
DCF Value
$2.93
FCF Yield
-121.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-80.4%
ROA
-64.3%
ROIC
-73.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-20.2M | $-1.88 |
| Q4 2025 | $0.00 | $-30.5M | $-2.94 |
| FY 2025 | $0.00 | $-116.8M | $-16.95 |
| Q3 2025 | $0.00 | $-26.9M | $-4.64 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$18.00
Target (Median)
$18.00
Target Range
$18.00 - $18.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.57
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies. This advanced modification is designed to achieve more precise targeting of tumors, enhance the body's natural and acquired immune responses against cancer, and provide sustained therapeutic benefits for patients. ADI-001, its most advanced therapeutic candidate, is presently in a Phase I clinical trial for individuals with non-Hodgkin's lymphoma. Additionally, Adicet Bio is developing ADI-002, which is undergoing preclinical investigations for its potential in treating a range of solid tumors. The company is headquartered in Boston, Massachusetts.